Metabolism and Excretory of HSK21542 in Maintenance Hemodialysis Patients

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 10, 2023

Primary Completion Date

November 21, 2023

Study Completion Date

February 27, 2024

Conditions

Chronic Kidney Disease Patients

Interventions

DRUG

HSK21542 Injection

A single intravenous dose of 0.8 μg/kg HSK21542 in boluses after D1 dialysis completed.

Trial Locations (1)

The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital), Jinan

All Listed Sponsors

lead

Haisco Pharmaceutical Group Co., Ltd.

INDUSTRY

NCT06238388 - Metabolism and Excretory of HSK21542 in Maintenance Hemodialysis Patients | Biotech Hunter | Biotech Hunter